Skip to main content

Linkage Biosciences Raises $2M in Series B Round

Premium

Linkage Biosciences said this week that it has closed a Series B financing round worth $2 million.

Linkage markets the LinkSeq HLA product line, which uses a proprietary software and chemistry platform in conjunction with real-time PCR instrumentation for HLA typing. According to the company, LinkSeq is an end-point PCR process that uses allele-specific amplification combined with SYBR Green to detect PCR products on the instrument using melt-curve analysis.

Fisher Capital and Greenhouse Capital Partners led the Series B round, which follows $2 million in Series A financing that the company raised in 2009 and $1 million in venture financing from Greenhouse Capital in 2007.

Linkage said it will use the funds to expand its manufacturing capabilities, complete regulatory requirements in the US and Europe, and accelerate the development of additional molecular tests.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.